By Fineline Cube 
China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. has entered into a strategic partnership with EVA Pharma, one of the fastest-growing healthcare organizations in the Middle East and Africa (MEA) region. The collaboration aims to jointly establish and enhance CAR-T cell therapy development and manufacturing capabilities at EVA Pharma’s facilities.
Collaboration Goals
This partnership marks a new era for personalized gene therapies targeting leukemia patients in Egypt, Saudi Arabia, and neighboring regions. The duo will focus on developing and producing high-quality lentiviral vectors, a critical component for CAR-T cell therapies against leukemia and other hematologic malignancies.
Technical Expertise
Porton Advanced will leverage its expertise in viral vector technology and Good Manufacturing Practice (GMP)-compliant cell therapy manufacturing. This support will enable EVA Pharma to deliver safe, effective, and scalable treatment solutions.-Fineline Info & Tech